ACLX Projected Dividend Yield
Arcellx Inc ( NASDAQ : ACLX )Arcellx, Inc. is a clinical-stage biotechnology company. Co. is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. Co.'s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). Co. is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). 21 YEAR PERFORMANCE RESULTS |
ACLX Dividend History Detail ACLX Dividend News ACLX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |